Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.66 |
| ▸ | AR | P10275 | 4/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.52 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25329541 | 1.00 | CRBN (0.66) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL31306523 | 0.93 | CRBN (0.66) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL20317461 | 0.91 | CRBN (0.79) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30144121 | 0.91 | CRBN (0.66) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL23860209 | 0.91 | CRBN (0.66) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL31447732 | 0.89 | CRBN (0.80) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL24421652 | 0.89 | CRBN (0.69) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL26969669 | 0.89 | CRBN (0.69) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL30160860 | 0.89 | CRBN (0.74) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL30692989 | 0.88 | CRBN (0.65) | CRBNARDDB1BTKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124516-A1 | COMPOUND HAVING AKT KINASE-DEGRADING ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 南京正大天晴制药有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-119836416-A | KAT6 targeting compounds with ubiquitin ligase binding moiety | 普莱鲁德疗法有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119019370-A | Degradation agent targeting SIRT6 and/or GSPT1 and application thereof | 深圳大学 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024213125-A1 | BRM SELECTIVE DEGRADATION AGENT AND USE THEREOF | 南京再明医药有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | PRELUDE THERAPEUTICS, INCORPORATED | 2023-12-28 | — | — | US | disclosed |
| WO-2023245150-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | KAT6A, KAT6B, KAT2A | CRBN 645/4885AR 699/4885DDB1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.